SYNOPSIS: Acutaas Chemicals Limited delivered a strong Q3 FY26 with sharp revenue, profit and EBITDA growth, driven by CDMO ramp-up, margin expansion, and an upward revision in revenue growth guidance.
During Wednesday’s trading session, shares of a leading global manufacturer of advanced pharmaceutical intermediates and speciality chemicals surged nearly 10 percent on BSE, after posting robust Q3 FY26 results marked by a sharp growth of around 48 percent QoQ and 134 percent YoY in net profit.
With a market cap of Rs. 15,264 crores, shares of Acutaas Chemicals Limited closed in the green at Rs. 1,864.45 on BSE, up by around 8 percent, as against its previous closing price of Rs. 1,728.95. The stock has delivered positive returns of over 98 percent in the last one year, and has gained by around 13 percent in the last one month.
Financial Performance for Q3 FY26
Acutaas Chemicals Limited announced the financial results for the third quarter of FY26 on Wednesday during market hours, as per the latest regulatory filings with the stock exchanges.
For the quarter, the company posted a consolidated revenue from operations of Rs. 393.2 crores, reflecting a sequential growth of over 28 percent QoQ compared to Rs. 306.2 crores in Q2 FY26. Likewise, on a year-on-year basis, revenue grew around 43 percent from Rs. 275 crores recorded in Q3 FY25.
Net profit for the quarter stood at Rs. 106.2 crore, indicating a significant increase of around 48 percent QoQ from Rs. 71.85 crores in Q2 FY26, as well as a rise on a year-on-year basis by nearly 134 percent from Rs. 45.44 crores reported in Q3 FY25.
Further, operating performance improved significantly during the quarter, EBITDA rose sharply to Rs. 150.7 crore from Rs. 68.7 crore in Q3 FY25, registering a growth of nearly 119 percent YoY. EBITDA margins also expanded to 38.3 percent from 25 percent.
The Advanced Pharmaceutical Intermediates (API) business delivered robust growth, supported by a strong ramp-up in the CDMO segment, while the specialty chemicals business continued to grow steadily. Cost-improvement measures and a favourable product mix improved gross margins. This, combined with operating leverage, drove strong EBITDA for the quarter. The improvement in EBITDA margins ultimately resulted in the company’s highest-ever PAT.
Management Guidance & More
Mr. Naresh Patel, Executive Chairman and Managing Director of the company, stated that Acutaas Chemicals sustained strong growth momentum in Q3, driven by the continued ramp-up of the CDMO segment. With a healthy order book and improved revenue visibility as the financial year draws to a close, the company has revised its revenue growth guidance upward from 25 percent to around 30 percent for FY26.
He further noted that the company continues to strengthen its core pharmaceutical intermediates business by adding CMO/CDMO opportunities, while also reinforcing its long-term foundation by scaling its battery chemicals and semiconductor chemicals verticals. These segments, which are currently under active capital investment, are progressing steadily toward scale and are expected to evolve into independent, self-sustaining growth engines over the next three years, contributing meaningfully to overall topline growth.
Acutaas Chemicals Limited, formerly known as Ami Organics Limited, is a speciality chemicals manufacturer serving a wide range of industries, including pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals. Its core strength lies in the research-driven development and manufacturing of advanced pharmaceutical intermediates used in both regulated and generic APIs, as well as intermediates for New Chemical Entities (NCEs).
In addition, the company’s offerings include parabens and their formulations, methyl salicylate, and niche key starting materials (KSMs) used in cosmetics and other industrial segments.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Chemical stock jumps 10% after its PAT increases by 134% YoY appeared first on Trade Brains.